50 cell and gene therapy leaders to watch in 2026

Cell and gene therapy enters 2026 as a field of potentially curative medicine with a stubbornly small customer base. The science has delivered one-time genetic interventions for diseases that once meant a lifetime of transfusions, progressive disability, or early death. The business model, in many cases, has not: these are expensive, operationally complex products that move through narrow treatment-center bottlenecks into reimbursement systems built for chronic care.

Bluebird Bio’s arc is perhaps the cleanest parable. A company that helped define modern gene therapy hit the same wall as much of the sector: breathtaking science, then a slow, expensive, operationally complex commercial rollout. By late 2024, only 57 patients had started treatment across bluebird’s three marketed gene therapies, a tough mismatch between scientific achievement and the economics of sustaining three concurrent launches, each with its own manufacturing line, treatment-center network, and reimbursement negotiation. In February 2025, Carlyle and SK Capital agreed to take the company private at $3 per share plus a contingent value right tied to sales milestones. By May, the buyers amended the deal to offer shareholders a second option: $5 cash up front with no CVR. The buyout closed on June 2, 2025, ending bluebird’s life as a public company. A few months later, it rebranded as Genetix Biotherapeutics, leaning into “back to the roots” messaging while promising operational rebuilding.

Bluebird’s trajectory illustrates a broader pattern. As the Cardinal Health 2025 Advanced Therapies Report noted, “CGT commercialization and access barriers drive the spread between market demand and adoption.”

“We think peak penetration could ultimately be constrained […].”
UBS Global Research, US Biotechnology, Jan. 6, 2026

Even when the biology works, the path to treatment still runs through high-intensity conditioning and specialized centers, which limits who can realistically make it to infusion.

That same reality is reshaping the broader field. Large players that once talked as if cell and gene therapy would be a portfolio cornerstone are backing away when timelines, manufacturing demands, and reimbursement math collide with other priorities. Takeda, for example, said on October 1, 2025 it would discontinue its cell therapy efforts and seek an external partner for its platform technologies and programs. Galapagos followed in early January 2026, announcing that its board had decided to initiate a wind-down of its cell therapy activities, a process expected to affect hundreds of employees and multiple sites.

The ranking that follows focuses on 50 companies across three profiles: commercial industrialists, late-stage clinical challengers, and emerging platform companies whose technology is already being pulled into real programs and deals. Even at the top, pressure is visible in the numbers: Gilead’s cell therapy sales fell 11 percent year-over-year in Q3 2025, to $432 million, citing “ongoing competitive headwinds.” Through the first three quarters, the franchise generated roughly $1.4 billion, on pace to decline from 2024’s $2 billion, even as Gilead added more than 40 authorized treatment centers globally.

Tier 1: Industrialists (12 companies)

 

Rank	Company	Lead Product(s)	2024 Revenue	Key Metric	Flag
1	Gilead/Kite	Yescarta, Tecartus	$2.0B	14-day U.S. turnaround	-11% Q3 YoY
2	Novartis	Zolgensma, Kymriah	$1.65B	4,500+ Zolgensma patients	Kymriah -14%
3	Legend/J&J	Carvykti	$963M	+110% YoY; OS benefit	Supply constraints
4	Bristol Myers Squibb	Breyanzi, Abecma	$1.15B	4 NHL subtypes	Abecma -14%
5	Sarepta	Elevidys	$821M	Only DMD gene therapy	3 deaths; FDA probe; boxed warning
6	Krystal Biotech	Vyjuvek	$291M	+473% YoY	First redosable GT
7	Iovance	Amtagvi	$104M	2025 guide: $450-475M	First solid tumor TIL
8	Vertex/CRISPR	Casgevy	$10M	First CRISPR approval	Slow ramp (typical)
9	PTC Therapeutics	Kebilidi	$807M (co.)	First GT to brain	Novartis $2.9B deal
10	Autolus	Aucatzyl	Pre-revenue	No REMS required	BioNTech $600M
11	Abeona	Zevaskyn	Pre-revenue	$226M cash post-PRV	First RDEB cell GT
12	Ultragenyx	DTX401 (BLA filed)	$555M (co.)	$745M cash	Recently filed a BLA for DTX401.

 

Tier 1 shows that CGT can generate real revenue, but it also shows where the bottlenecks concentrate: manufacturing slots, center bandwidth, and the practical limits of who can be conditioned, collected, and reimbursed. The same pattern is now shaping expectations for gene editing, where the hurdle is often not whether a therapy can work, but how many patients can realistically reach it.

“VRTX is exploring gentler conditioning regimens (‘chemo-free’ conditioning) which could eliminate the need for myeloablative conditioning and expand the market for gene editing therapies in sickle cell.”

UBS Global Research, US Biotechnology, Jan. 6, 2026

Tier 2: Clinical challengers (25 companies)

---

Tier 3: Next-Gen Innovators & Platforms (13 companies)

Other prominent players

These companies remain active in the CGT space:

Legacy approved products:

• Roche/Spark: Luxturna revenue -59% YoY; $2.4B impairment taken on Spark unit
• CSL Behring/uniQure: Hemgenix: 75+ patients treated globally across eight countries; $3.5M price
• BioMarin: Announced Roctavian divestiture October 2025 after disappointing uptake
• Orchard/Kyowa Kirin: Libmeldy/Lenmeldy revenue 33% below target

Clinical-stage with uncertainty:

• Sana Biotechnology: Hypoimmune platform differentiated but roughly 12-month runway
• Century Therapeutics: BMS partnership terminated March 2025
• Astellas Gene Therapies: AT132 on clinical hold since 2021 (4 deaths)
• Encoded Therapeutics: Positive Dravet data but 29% layoffs
• IN8bio: γδ T-cell therapy for GBM showing early promise, but $30M cash creates existential 2026 risk under Business Health criteria (40% weight)
• Precision BioSciences: ARCUS gene editing platform with Phase 1 HBV program; $71M cash insufficient for pivotal path without partnership or raise

Emerging platforms (pre-clinical validation):

• nChroma Bio: Formed via Chroma Medicine/Nvelop merger with $75M financing; epigenetic editing platform compelling but no human data yet; Tune Therapeutics (Phase 1b, $175M Series B) currently leads clinically
• Ring Therapeutics: Flagship-backed anellovirus platform represents novel vector approach; requires clinical proof-of-concept to justify Top 50 inclusion over late-stage competitors
• Galapagos: Board announced cell therapy wind-down January 5, 2026; disqualifying for CGT leaders list

Platform/Tools:

• Asimov: Genetic circuit design platform with Cytiva and DARPA backing; valuable enabling technology but better characterized as tools company than CGT leader
• Obsidian Therapeutics: cytoDRiVE regulatable platform; BMS investor
• Affini-T Therapeutics: TCR-T for KRAS/P53; $193M raised

---

Filed Under: Cell & gene therapy
Tagged With: Biopharma M&A, biotechnology trends 2026, Bluebird Bio, CAR-T, Carvykti, Casgevy, cell and gene therapy, CGT, commercialization challenges, CRISPR Therapeutics, Elevidys, Galapagos, gene editing, Genetix Biotherapeutics, Gilead Sciences, manufacturing bottlenecks, market consolidation, Reimbursement, Sarepta Therapeutics, Takeda, Vertex Pharmaceuticals, Yescarta
 

---